Reimagining Medicine
Company overview
Innovation: Pipeline overview
Cardiovascular
JakaviⓇ - JAK1/2 inhibitor
NCT03491215 REACH4 (CINC424F12201)
Indication
Acute graft versus host disease
Phase 2
Financial review
Immunology
Phase
Patients
45
Primary
Outcome
Measurement of PK parameters
Measures
Overall Response Rate (ORR)
Arms
Ruxolitinib
2023 priorities
Innovation: Clinical trials
Neuroscience
Intervention
Pediatric patients with grade II-IV acute graft vs. host disease after allogeneic
hematopoietic stem cell transplantation
Target
Patients
Readout
2023
Milestone(s)
Publication
TBD
85 Investor Relations | Q4 2022 Results
Oncology
JakaviⓇ- JAK1/2 inhibitor
NCT03774082 REACH5 (CINC424G12201)
Appendix
Abbreviations
Other
Indication
Phase
Chronic graft versus host disease
Phase 2
Patients
45
Primary
Overall Response Rate (ORR)
Outcome
Measures
Arms
Ruxolitinib 5mg tablets / pediatric formulation
Intervention
Target
Patients
Pediatric subjects with moderate and severe chronic Graft vs. Host disease
after allogeneic stem cell transplantation
Readout
Milestone(s)
Publication
2023
TBD
NOVARTIS | Reimagining MedicineView entire presentation